The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q4 2016 call → NOWe need to determine if management conveys that the reported results for Q4 2016 do not represent the business as it is actually running today. The call discusses 2016 results and 2017 guidance. Key points: management discusses a broad lung cancer program, but also notes that the competitive landscape has changed. They mention that they have expanded and strengthened their lung program over the last several months. They also discuss that they have four combination front-line lung studies ongoing. They talk about the potential for earlier entry of Keytruda/chemo combo, which affects 2017 outlook. They also mention that they have stopped promotional activities for hep C in the U.S. and expect decline to accelerate. They discuss that they have a broad I-O program with many assets. They also mention that they have a positive patent litigation resolution with Merck. They talk about 2017 priorities including building on Eliquis and Orencia, and advancing pipeline in heart failure, immuno-science, fibrosis. They mention early data readouts expected in systemic lupus, NASH, psoriasis. The question is whether management conveys that the reported results are stale relative to the operating present. The call is a standard earnings call with results and outlook. Management discusses 2016 performance and 2017 guidance. They do mention that the lung cancer program has been expanded and strengthened, and that they have a broad program. But they also acknowledge that the competitive landscape has changed. They talk about the potential for earlier entry of Keytruda/chemo combo, which affects 2017 outlook. They also mention that they have stopped promotional activities for hep C. They discuss that they have a broad I-O pipeline with many assets. They also mention that they have a positive patent litigation resolution. However, the question is specifically about whether management conveys that the reported results do not represent the business as it is actually running today. That is, does management indicate that the just-reported numbers describe a company that has already been left behind by what is now actually happening inside the business? This would be a case where management says something like "the reported period is stale, we have already moved on to a different level of business." In this call, management does not seem to be saying that.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.